CompletedNCT01129882
Long-term injectable aripiprazole for people with schizophrenia
About this title
Read the official source — NCT01129882Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- Bellevue and 156 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 24, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 709
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Argentina, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01129882
- Official title
Show the full official title
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bellevue, United States · Garden Grove, United States · Glendale, United States
127 more locations
- Imperial, United States
- Los Angeles, United States
- National City, United States
- Orange, United States
- Pasadena, United States
- Pico Rivera, United States
- San Bernardino, United States
- San Diego, United States
- Sherman Oaks, United States
- Norwalk, United States
- Washington D.C., United States
- Bradenton, United States
- Doral, United States
- Hialeah, United States
- Homestead, United States
- Orange City, United States
- Tampa, United States
- Chicago, United States
- Oak Brook, United States
- Indianapolis, United States
- Shreveport, United States
- Flowood, United States
- St Louis, United States
- North Platte, United States
- Buffalo, United States
- New York, United States
- Queens, United States
- Rochester, United States
- Charlotte, United States
- Akron, United States
- Canton, United States
- Toledo, United States
- Oklahoma City, United States
- Allentown, United States
- Jenkintown, United States
- Sellersville, United States
- Charleston, United States
- Memphis, United States
- Austin, United States
- DeSoto, United States
- Richmond, United States
- Bothell, United States
- Milwaukee, United States
- Buenos Aires, Argentina
- Mendoza, Argentina
- Epping, Australia
- Frankston, Australia
- Fremantle, Australia
- Burgas, Bulgaria
- Lovech, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Radnevo, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Tserova Koria, Bulgaria
- Varna, Bulgaria
- Santiago, Chile
- Temuco, Chile
- Valdivia, Chile
- Zagreb, Croatia
- Tallinn, Estonia
- Tartu, Estonia
- Viljandi, Estonia
- Helsinki, Finland
- Baja, Hungary
- Balassagyarmat, Hungary
- Gyõr, Hungary
- Ahmedabad, India
- Mangalore, India
- Bangalore, India
- Chennai, India
- Kanpur, India
- Pune, India
- Tirupati, India
- Ipoh, Malaysia
- Kajang, Malaysia
- Kuala Lumpur, Malaysia
- Guadalajara, Mexico
- Monterrey, Mexico
- Culiacán, Mexico
- México, Mexico
- San Luis Potosí City, Mexico
- Mandaluyong, Philippines
- Iloilo City, Philippines
- Mariveles, Philippines
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Choroszcz, Poland
- Krakow, Poland
- Leszno, Poland
- Sosnowiec, Poland
- Wroclaw, Poland
- San Juan, Puerto Rico
- Arad, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Oradea, Romania
- Piteşti, Romania
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Smolensk, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Bardejov, Slovakia
- Košice, Slovakia
- Liptovský Mikuláš, Slovakia
- Prešov, Slovakia
- Rimavská Sobota, Slovakia
- Cape Town, South Africa
- Bellville, South Africa
- Pretoria West, South Africa
- Daejeon, South Korea
- Gwangju, South Korea
- Incheon, South Korea
- Seoul, South Korea
- Barcelona, Spain
- L'Hospitalet de Llobregat, Spain
- Tainan, Taiwan
- Taipei, Taiwan
- Chiang Mai, Thailand
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia